Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 1
2014 6
2015 3
2016 2
2017 5
2018 3
2019 1
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Karmali R, Abramson JS, Stephens DM, Barnes J, Winter JN, Ma S, Gao J, Kaplan J, Petrich AM, Hochberg E, Takvorian T, Mi X, Nelson V, Gordon LI, Pro B. Karmali R, et al. Among authors: petrich am. Blood Adv. 2023 Dec 12;7(23):7361-7368. doi: 10.1182/bloodadvances.2023011271. Blood Adv. 2023. PMID: 37756532 Free PMC article.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F. Zelenetz AD, et al. Among authors: petrich am. Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8. Blood. 2019. PMID: 30850381 Free PMC article. Clinical Trial.
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B. Pearse WB, et al. Among authors: petrich am. Leuk Lymphoma. 2021 Dec;62(14):3493-3500. doi: 10.1080/10428194.2021.1957867. Epub 2021 Aug 2. Leuk Lymphoma. 2021. PMID: 34338127 Clinical Trial.
27 results